A carregar...
Immunotherapy for Glioblastoma: Current Progress and Challenges
Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15 months when treated with the current standard of care, which consists of surgery, radiotherapy and chemotherapy. With the recent success of immunotherapy in other aggressive cancers such as advanced melanoma and...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8158294/ https://ncbi.nlm.nih.gov/pubmed/34054867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.676301 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|